• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

自适应磁共振引导立体定向体部放射治疗：肾癌治疗的下一步。

Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma.

作者信息

Keller Brian, Bruynzeel Anna M E, Tang Chad, Swaminath Anand, Kerkmeijer Linda, Chu William

机构信息

Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, Netherlands.

出版信息

Front Oncol. 2021 May 11;11:634830. doi: 10.3389/fonc.2021.634830. eCollection 2021.

DOI:10.3389/fonc.2021.634830
PMID:34046341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8144516/
Abstract

Adaptive MR-guided radiotherapy (MRgRT) is a new treatment paradigm and its role as a non-invasive treatment option for renal cell carcinoma is evolving. The early clinical experience to date shows that real-time plan adaptation based on the daily MRI anatomy can lead to improved target coverage and normal tissue sparing. Continued technological innovations will further mitigate the challenges of organ motion and enable more advanced treatment adaptation, and potentially lead to enhanced oncologic outcomes and preservation of renal function. Future applications look promising to make a positive clinical impact and further the personalization of radiotherapy in the management of renal cell carcinoma.

摘要

自适应磁共振引导放疗（MRgRT）是一种新的治疗模式，其作为肾细胞癌的非侵入性治疗选择的作用正在不断发展。迄今为止的早期临床经验表明，基于每日MRI解剖结构的实时计划调整可提高靶区覆盖范围并减少正常组织受照剂量。持续的技术创新将进一步缓解器官运动带来的挑战，并实现更先进的治疗调整，有可能提高肿瘤治疗效果并保留肾功能。未来的应用有望产生积极的临床影响，并进一步推动肾细胞癌治疗中放疗的个性化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f851/8144516/7245853638e4/fonc-11-634830-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f851/8144516/1d390e1558bd/fonc-11-634830-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f851/8144516/7245853638e4/fonc-11-634830-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f851/8144516/1d390e1558bd/fonc-11-634830-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f851/8144516/7245853638e4/fonc-11-634830-g002.jpg

相似文献

1
Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma.自适应磁共振引导立体定向体部放射治疗：肾癌治疗的下一步。
Front Oncol. 2021 May 11;11:634830. doi: 10.3389/fonc.2021.634830. eCollection 2021.
2
MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.磁共振引导自适应与 ITV 基础立体定向体部放疗治疗肝转移瘤（MAESTRO）：一项随机对照的 II 期临床试验。
Radiat Oncol. 2022 Mar 27;17(1):59. doi: 10.1186/s13014-022-02033-2.
3
Initial clinical experience with magnetic resonance-guided radiotherapy in pediatric patients: Lessons learned from a single institution with proton therapy.小儿患者磁共振引导放疗的初步临床经验：来自单一质子治疗机构的经验教训
Front Oncol. 2023 Jan 11;12:1037674. doi: 10.3389/fonc.2022.1037674. eCollection 2022.
4
Medical physics challenges in clinical MR-guided radiotherapy.临床磁共振引导放射治疗中的医学物理学挑战。
Radiat Oncol. 2020 May 5;15(1):93. doi: 10.1186/s13014-020-01524-4.
5
A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).一项随机 II 期试验研究了 MR 引导下前列腺立体定向体部放疗，对于局限性前列腺癌（FORT）患者分别采用 5 或 2 个剂量分割进行治疗。
BMC Cancer. 2023 Sep 30;23(1):923. doi: 10.1186/s12885-023-11430-z.
6
Towards Accurate and Precise Image-Guided Radiotherapy: Clinical Applications of the MR-Linac.迈向精确的图像引导放射治疗：磁共振直线加速器的临床应用
J Clin Med. 2022 Jul 13;11(14):4044. doi: 10.3390/jcm11144044.
7
Feasibility of Adaptive MR-guided Stereotactic Body Radiotherapy (SBRT) of Lung Tumors.自适应磁共振引导的肺部肿瘤立体定向体部放射治疗（SBRT）的可行性
Cureus. 2018 Apr 4;10(4):e2423. doi: 10.7759/cureus.2423.
8
First 500 Fractions Delivered with a Magnetic Resonance-guided Radiotherapy System: Initial Experience.使用磁共振引导放射治疗系统输送的前500次分次治疗：初步经验。
Cureus. 2019 Dec 24;11(12):e6457. doi: 10.7759/cureus.6457.
9
Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments.美国0.35特斯拉磁共振引导放射治疗的使用模式与临床应用——理解向适应性超分割治疗的转变
Clin Transl Radiat Oncol. 2022 Nov 22;38:161-168. doi: 10.1016/j.ctro.2022.11.013. eCollection 2023 Jan.
10
Initial Clinical Experience of MR-Guided Radiotherapy for Non-Small Cell Lung Cancer.磁共振引导下非小细胞肺癌放射治疗的初步临床经验
Front Oncol. 2021 Mar 10;11:617681. doi: 10.3389/fonc.2021.617681. eCollection 2021.

引用本文的文献

1
MR-LINAC, a New Partner in Radiation Oncology: Current Landscape.磁共振直线加速器，放射肿瘤学的新伙伴：当前概况
Cancers (Basel). 2024 Jan 8;16(2):270. doi: 10.3390/cancers16020270.
2
Adding Stereotactic Radiation to the Multidisciplinary Armamentarium for Localized Renal Cell Carcinoma: Ready for Primetime? : An Editorial Regarding a Recent 5-Year Efficacy and Safety Report of a Multicenter Cohort of Primary RCC Patients Treated with SABR.将立体定向放射治疗纳入局限性肾细胞癌多学科治疗手段：时机已到？：关于一项原发性肾细胞癌患者多中心队列接受立体定向体部放射治疗的近期5年疗效与安全性报告的述评
Ann Surg Oncol. 2023 Nov;30(12):6947-6949. doi: 10.1245/s10434-023-13755-2. Epub 2023 Jun 19.
3

本文引用的文献

1
Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.立体定向放射治疗用于接受酪氨酸激酶抑制剂治疗的转移性肾细胞癌患者的寡进展：一项2期前瞻性多中心研究
Eur Urol. 2021 Dec;80(6):693-700. doi: 10.1016/j.eururo.2021.07.026. Epub 2021 Aug 13.
2
Patient-reported Quality of Life following Stereotactic Body Radiation Therapy for Primary Kidney Cancer - Results from a Prospective Cohort Study.患者报告的立体定向体部放射治疗原发性肾癌后的生活质量 - 一项前瞻性队列研究的结果。
Clin Oncol (R Coll Radiol). 2021 Jul;33(7):468-475. doi: 10.1016/j.clon.2021.03.002. Epub 2021 Mar 26.
3
Stereotactic Magnetic Resonance-Guided Adaptive and Non-Adaptive Radiotherapy on Combination MR-Linear Accelerators: Current Practice and Future Directions.
基于磁共振线性加速器组合的立体定向磁共振引导自适应与非自适应放射治疗：当前实践与未来方向。
Cancers (Basel). 2023 Mar 30;15(7):2081. doi: 10.3390/cancers15072081.
4
Assessing organ at risk position variation and its impact on delivered dose in kidney SABR.评估肾脏 SABR 中危及器官位置变化及其对剂量分布的影响。
Radiat Oncol. 2022 Jun 27;17(1):112. doi: 10.1186/s13014-022-02041-2.
KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer.
KDIGO肿瘤肾脏病学争议会议：了解肾功能损害与实体器官恶性肿瘤，以及肾癌的管理
Kidney Int. 2020 Nov;98(5):1108-1119. doi: 10.1016/j.kint.2020.06.046.
4
ADC measurements on the Unity MR-linac - A recommendation on behalf of the Elekta Unity MR-linac consortium.Unity MR-Linac 上的 ADC 测量 - Elekta Unity MR-Linac 联盟的建议。
Radiother Oncol. 2020 Dec;153:106-113. doi: 10.1016/j.radonc.2020.09.046. Epub 2020 Oct 2.
5
The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy.动量研究：基于证据引入磁共振引导自适应治疗的国际注册研究。
Front Oncol. 2020 Sep 7;10:1328. doi: 10.3389/fonc.2020.01328. eCollection 2020.
6
The Role of Daily Adaptive Stereotactic MR-Guided Radiotherapy for Renal Cell Cancer.每日适应性立体定向磁共振引导放疗在肾细胞癌治疗中的作用
Cancers (Basel). 2020 Sep 25;12(10):2763. doi: 10.3390/cancers12102763.
7
Treatment plan quality during online adaptive re-planning.在线自适应重计划期间的治疗计划质量。
Radiat Oncol. 2020 Aug 21;15(1):203. doi: 10.1186/s13014-020-01641-0.
8
Initial clinical experience of Stereotactic Body Radiation Therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 Tesla MR-Linac.基于 4D-MRI 的在线自适应和使用 1.5T MR-Linac 的实时 MRI 监测的立体定向体部放射治疗（SBRT）在肝转移、原发性肝癌和胰腺癌中的初步临床经验。
PLoS One. 2020 Aug 7;15(8):e0236570. doi: 10.1371/journal.pone.0236570. eCollection 2020.
9
Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK).立体定向消融放疗治疗≥T1b期原发性肾细胞癌：来自国际肾脏放射外科肿瘤学联盟（IROCK）的报告
Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):941-949. doi: 10.1016/j.ijrobp.2020.06.014. Epub 2020 Jun 17.
10
Reliability of ITV approach to varying treatment fraction time: a retrospective analysis based on 2D cine MR images.基于 2D 电影磁共振图像的治疗分次时间变化的 ITV 方法的可靠性：回顾性分析。
Radiat Oncol. 2020 Jun 12;15(1):152. doi: 10.1186/s13014-020-01530-6.